Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction

Transplantation

Volumn 97, Issue 1, 2014, Pages 56-63

  Kubal, Chandrashekhar A ^a   Mangus, Richard S ^a   Saxena, Romil ^a   Lobashevsky, Andrew ^b   Higgins, Nancy ^b   Agarwal, Avinash ^c   Fridell, Jonathan A ^a   Tector, A Joseph ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Acute rejection; Alloantibody; Chronic rejection; Crossmatch; Graft loss; Liver transplant; Sensitized recipient

Indexed keywords

EID: 84892973955     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a688c0     Document Type: Article

References (32)

1. Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18: 455.
2. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868.
3. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504.
4. Starzl TE, Ishikawa M, Putnam CW, et al. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc 1974; 6: 129.
5. Iwatsuki S, Iwaki Y, Kano T, et al. Successful liver transplantation from crossmatch-positive donors. Transplant Proc 1981; 13: 286.
6. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg 1996; 224: 168.
7. Nikaein A, Backman L, Jennings L, et al. HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation 1994; 58: 786.
8. Bathgate AJ, McColl M, Garden OJ, et al. The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg 1998; 4: 280.
9. Muro M, Marin L, Miras M, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allo-graft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: 91.
10. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554.
11. Lang M, Neumann U, Knoop M, et al. Impact of immunosuppression in liver transplantation across a positive crossmatch. Transplant Proc 1998; 30: 1466.
12. Goggins WC, Fisher RA, Kimball PM, et al. The impact of a positive crossmatch upon outcome after liver transplantation. Transplantation 1996; 62: 1794.
13. Batts KP, Moore SB, Perkins JD, et al. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376.
14. Takaya S, Jain A, Yagihashi A, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31: 2028.
15. Wahrmann M, Exner M, Schillinger M, et al. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 2006; 6: 1033.
16. Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012; 16: 12.
17. Ata P, Canbakan M, Kara M, et al. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization. Transplant Proc 2012; 44: 1652.
18. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T-or B-cell crossmatch-positive patients. Transplantation 2003; 76: 1444.
19. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
20. Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6: 2384.
21. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171.
22. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638.
23. Martin F, Chan AC. Pathogenic roles of B cells in human autoim-munity; insights from the clinic. Immunity 2004; 20: 517.
24. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467.
25. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
26. Vianna RM, Mangus RS, Fridell JA, et al. Induction immunosuppres-sion with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 2008; 85: 1290.
27. Mangus RS, Fridell JA, Vianna RM, et al. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up. Liver Transpl 2012; 18: 786.
28. Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011; 91: 342.
29. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121.
30. Milkiewicz P, Gunson B, Saksena S, et al. Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors. Transplantation 2000; 70: 477.
31. Nakamura K, Murase N, Becich MJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 1383.
32. Lobashevsky AL SR, Shoaf J, et al. Specificity of preformed alloanti-bodies causing B cell positive flow crossmatch in renal transplantation. Clin Transplant 2000; 14: 533.